Results 151 to 160 of about 7,657 (243)

Hématome épidural rachidien spontané en cas de dorsalgie aiguë [PDF]

, 2017
Anisau, Aliaksandr, Vangeneugden, Johan, Vanhoenacker, Filip   +2 more
core   +1 more source

Diverging Safety Signals: A Trend Analysis of Suspected Adverse Drug Reactions Reporting for Spinal Muscular Atrophy Therapies in the European Union. [PDF]

Neurol Int
Belančić A, Mas P, Stević I, Vitezić D, Janković S.   +4 more
europepmc   +1 more source

Real-world evidence of Nusinersen treatment for patients with spinal muscular atrophy in the Kingdom of Saudi Arabia: Initial insights from the Saudi national spinal muscular atrophy program. [PDF]

Saudi Med J
Al-Jedai AH, Almudaiheem HY, Alaama TY, Alsaman ASS, Abdo Bashiri F, Almuhaizae MA, Alghamdi FA, Alsakran AA, Matter EAY, Ibrahim FZ.   +9 more
europepmc   +1 more source

Five-year disease-modifying therapeutic experience of 102 Chinese paediatric 5q-spinal muscular atrophy: a retrospective analysis. [PDF]

Brain Commun
Jiang M, Liang C, Zhang Y, Zheng K, Xu K, He L, Tao J, Wu W, Zheng R, Rao M, Zhang W, Zhou W, Liu L.   +12 more
europepmc   +1 more source

A therapeutic antisense oligonucleotide encompassing 2'-<i>O</i>-methoxyethyl modification triggers unique perturbation of the transcriptome. [PDF]

NAR Mol Med
Ottesen EW, Murzyn WA, Kaas RL, Bertrand KJ, Payne JL, Singh RN.   +5 more
europepmc   +1 more source

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. [PDF]

Nat Med
Kwon JM, Munell F, Le Goff L, Yuge K, Kato T, Cances C, De Waele L, Woodcock IR, Mercuri EM, Proud CM, Darras BT, Hayes LH, Oskoui M, Visootsak J, Williams G, Ilić A, Yang L, van der Pol WL.   +17 more
europepmc   +1 more source

Transforming Spinal Muscular Atrophy: From Pivotal Trials to Real-World Evidence and Future Therapeutic Frontiers in Types 1 and 2. [PDF]

Biomedicines
Belančić A, Eustaquio PC, Gkrinia EMM, Rački V, Pilipović K, Vitezić D.   +5 more
europepmc   +1 more source

Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements. [PDF]

Cost Eff Resour Alloc
Al-Jedai A, Al-Mudaiheem H, AlSakran A, Bashiri FA, Ghamdi F, Almuhaizea MA, AlSamman A, Awad N, Ojeil R.   +8 more
europepmc   +1 more source

Moving Beyond Population-Level Analyses to Characterize Individual Heterogeneity in CMAP Responses Would Enhance the Assessment of Its Clinical Utility. [PDF]

Eur J Neurol
Zhang Y, Hu J, Pu Y, Bai X.
europepmc   +1 more source